BioCentury
ARTICLE | Clinical News

Abbott adds $4.3B on HCV data

October 16, 2012 1:33 AM UTC

Abbott Laboratories (NYSE:ABT) added $4.3 billion in market cap on Monday after reporting data from the Phase IIb Aviator trial of an interferon-free regimen that includes three of Abbott's antivirals to treat HCV genotype 1 infection. The regimen -- ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 12 weeks -- produced a sustained virologic response 12 weeks after the end of treatment in 99% of treatment-naive patients (n=77) and 93% of null responders (n=41). One treatment-naive patient relapsed and three null responders experienced viral breakthrough. On Monday, Abbott's stock gained $2.77 to $72.05, valuing the company at $113 billion. ...